On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors. Ouimet discussed market resilience amidst political friction between the US Supreme Court and President Donald Trump. He stated that while a Supreme Court decision had been reached, the administration’s push for a 10% global tariff suggested that trade uncertainties remain.
Despite this, he maintained a positive outlook and noted that political pressures may prevent an overly aggressive tariff stance and that broader economic fundamentals remain strong. He expressed surprise at the lack of market reaction to these events, particularly in the bond market, where he expected more volatility given a potential $200 billion Treasury reimbursement. However, he noted that Treasury Secretary Bessent remains unconcerned as revenues continue to accrue.
Under the slogan ‘Make Portfolios Diversified Again,’ Ouimet explained his strategy of reducing exposure to US dollar-denominated assets in favor of repatriating capital to Canada or investing in jurisdictions like Europe. He emphasized the importance of wide diversification rather than focusing on a single trend or sector.
While he remains selective within the tech sector, he continues to see buoyancy in the AI theme. He observed that AI is currently in a third wave of development, evidenced by recent weakness in software stocks as the tech continues to evolve rapidly. Regarding undervalued sectors, Ouimet highlighted energy as an area offering attractive free cash flow yields despite a lack of investor love. He also pointed to the mining sector, specifically gold, as a strong play.
That being said, we’re here with a list of the 12 dirt cheap stocks to buy now.
Our Methodology
We used screeners to identify stocks that are trading below a forward P/E of 10 and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on March 2.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
12 Dirt Cheap Stocks to Buy Now
12. Fidelity National Financial Inc. (NYSE:FNF)
Fidelity National Financial Inc. (NYSE:FNF) is one of the dirt cheap stocks to buy now. On February 20, Fidelity National Financial reported strong financial results for Q4 and the full year of 2025, highlighted by total annual revenue of $14.5 billion, a 7% increase over the previous year. The title segment performed robustly, achieving adjusted pre-tax earnings of $401 million in Q4 with an industry-leading margin of 17.5%.
For the full year, adjusted net earnings reached $1.4 billion, or $4.97 per diluted share, despite a reported net loss of $117 million in the final quarter. The company’s growth was supported by a 27% year-over-year increase in direct commercial revenue, which reached $479 million in Q4. Additionally, the FNG segment saw assets under management rise 12% to $73.1 billion, with gross sales hitting $14.6 billion for the year.
Technological integration played a key role in these operational successes, as Fidelity National Financial Inc.’s (NYSE:FNF) digital transaction platform engaged 80% of residential sale transactions in 2025. This digital reach extended to 2.8 million unique users, proving that the company’s technology investments have scaled effectively.
Fidelity National Financial Inc. (NYSE:FNF), together with its subsidiaries, provides various insurance products in the United States. The company has Title, F&G, and Corporate & Other segments.
11. Viatris Inc. (NASDAQ:VTRS)
Viatris Inc. (NASDAQ:VTRS) is one of the dirt cheap stocks to buy now. On February 26, Viatris reported a steady financial performance for the full-year 2025, generating $14.3 billion in total revenue, a 2% increase over the previous year when excluding Indore-related impacts. The company achieved an adjusted EBITDA of $4.2 billion and an adjusted EPS of $2.35, supported by $2.2 billion in free cash flow.
The company’s initiatives were marked by significant regulatory progress, including five positive Phase III readouts and the completion of 60 regional transactions, such as the acquisition of Aculys Pharma in Japan. For 2026, Viatris anticipates total revenue and adjusted EBITDA growth of approximately 2%, with new product revenue expected to contribute between $450 million and $550 million.
To support long-term competitiveness, a strategic review identified $650 million in gross cost savings to be realized through 2029, with a portion earmarked for reinvestment. Despite these gains, Viatris Inc. (NASDAQ:VTRS) faces headwinds, including uncertain FDA reinspection timing for its Indore facility and anticipated gross margin declines due to losses of exclusivity and product mix shifts.
Viatris Inc. (NASDAQ:VTRS), together with its subsidiaries, operates as a healthcare company internationally. It has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
